589 results on '"Iborra, M."'
Search Results
2. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
3. Letter to the Editor on The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate–Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study
4. Protocolo diagnóstico y terapéutico de las formas agudas graves de colitis ulcerosa
5. Enfermedad de Whipple
6. P650 Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world
7. OP37 Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU
8. P989 Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU
9. P516 Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes
10. P657 Persistence of subcutaneous infliximab after two years of the switch from intravenous infliximab to subcutaneous infliximab in Inflammatory Bowel Disease patients
11. An observational longitudinal study to evaluate tools and strategies available for the diagnosis of Congenital Chagas Disease in a non-endemic country
12. Supplier behavior and its impact on customer satisfaction: A new characterization of negotiation behavior
13. The Clinical and Parasitologic Follow-up of Trypanosoma cruzi–infected Children in a Nonendemic Country
14. Risk of postoperative morbidity in patients having bowel resection for colonic Crohn’s disease
15. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab
16. DOP17 HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry
17. P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
18. P652 Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response
19. OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
20. Thermodynamic equilibrium for the dehydration of 1-butanol to di-n-butyl ether
21. Ion exchange resins as catalysts for the liquid-phase dehydration of 1-butanol to di-n-butyl ether
22. Kinetics of 1-hexanol etherification on Amberlyst 70
23. Internal Employability as a Strategy for Key Employee Retention
24. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
25. Diagnóstico y tratamiento de la enfermedad de Chagas
26. How BATNAs perception impacts JVs negotiations
27. P583 Trends in endoscopy management after surgery in a national cohort of Spanish Crohnʼs disease patients. Results from PRACTICROHN study
28. P365 Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
29. OP013 Disease management and outcomes of patients with Crohnʼs disease at high risk of recurrence. Results from PRACTICROHN study
30. Negotiating behavior in service outsourcing. An exploratory case study analysis
31. Catalytic Activity and Accessibility of Acidic Ion-Exchange Resins in Liquid Phase Etherification Reactions
32. Study of the oligomerization of 1-octene catalyzed by macroreticular ion-exchange resins
33. Synthesis of ethyl octyl ether from diethyl carbonate and 1-octanol over solid catalysts. A screening study
34. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
35. Hacia una perspectiva integradora de la teoría de grupos estratégicos: validez convergente y fortaleza de la definición de grupo estratégico
36. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
37. Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia
38. La discapacidad es trending topic: análisis del impacto en Twitter de diez campañas de sensibilización
39. The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease
40. Los objetivos de desarrollo sostenible y la agenda 2030 en la formación inicial del profesorado
41. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
42. Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
43. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
44. Doru Costache, Humankind and the Cosmos: Early Christian Representations, Brill, Leiden / Boston 2021, 436 pp. [RESEÑA]
45. The influence of gender role on negotiation development and outcome : A proposal for strategic alliance negotiations
46. Liquid-phase dehydration of 1-octanol, 1-hexanol and 1-pentanol to linear symmetrical ethers over ion exchange resins
47. P118 Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
48. POSC354 Treatment of Iron Deficiency without Anemia with Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease: Prospective Evaluation of Clinical and Patient-Reported Outcomes in Spain
49. P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
50. P292 Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.